Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond

Standard chemotherapy for adrenocortical cancer currently is under evaluation in the context of the recently completed FIRM-ACT evaluating the combination of mitotane with either streptozocin or etoposide, cisplatin, and doxorubicin. New agents are eagerly sought by the ACC community that hopes to make progress against this deadly disease. Investigators have begun to dissect the molecular and genomic context of ACC with a goal of identifying potential novel therapeutic agents. One gene consistently overexpressed in ACC is insulin growth factor type 2. Targeting its receptor IGF1R has shown encouraging results in ACC cell lines and against murine xenografts. As a result, clinical trials to evaluate agents targeting the IGF1R have been done including mitotane and IMC-A12 (a monoclonal antibody) and the GALACCTIC trial that has just completed accrual to evaluate OSI-906, a small molecule IGF1R antagonist. On the horizon are other agents targeting other tyrosine kinases, including EGF and FGF, and novel strategies such as individualized tumor analysis to select treatment.

[1]  A. Takaoka,et al.  Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.

[2]  F. Berger,et al.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. , 2005, The Journal of clinical endocrinology and metabolism.

[3]  Hong Chang,et al.  CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. , 2004, Blood.

[4]  Xia Han,et al.  The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. , 2009, Cancer research.

[5]  W. Oh,et al.  A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC) , 2007 .

[6]  L. Santarpia,et al.  The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. , 2010, Endocrine reviews.

[7]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[8]  Helen X. Chen,et al.  Adverse effects of anticancer agents that target the VEGF pathway , 2009, Nature Reviews Clinical Oncology.

[9]  Bertrand Dousset,et al.  Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Garber.  Drugging the Wnt pathway: problems and progress. , 2009, Journal of the National Cancer Institute.

[11]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[12]  G. Riggins,et al.  Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling , 2009, Journal of Neuro-Oncology.

[13]  R. Kurzrock,et al.  Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials , 2008, Molecular Cancer Therapeutics.

[14]  S. Giordano,et al.  ReviewMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapy , 2015 .

[15]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[16]  P. Adam,et al.  Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. , 2009, Endocrine-related cancer.

[17]  G. Hostetter,et al.  Preclinical Investigation of Nanoparticle Albumin-Bound Paclitaxel as a Potential Treatment for Adrenocortical Cancer , 2012, Annals of surgery.

[18]  Leah M. Cook,et al.  Metastasis suppressors and the tumor microenvironment. , 2011, Seminars in cancer biology.

[19]  Ronald G Blasberg,et al.  Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. , 2010, Cancer research.

[20]  M. Seki,et al.  Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis , 1992, Human Genetics.

[21]  F. Esteva,et al.  Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[22]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[23]  D. Boyd,et al.  Insulin and Cancer , 2003, Integrative cancer therapies.

[24]  E. Lalli,et al.  Gene expression profiling of childhood adrenocortical tumors. , 2007, Cancer research.

[25]  Takashi Suzuki,et al.  Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  M. Neeman,et al.  Molecular and Cellular Pathobiology p 53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF 1-Dependent Manner , 2010 .

[27]  J. Curtin,et al.  Drug Discovery Approaches to Target Wnt Signaling in Cancer Stem Cells , 2010, Oncotarget.

[28]  P. Neven,et al.  Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy , 2008, Oncogene.

[29]  D. Bartsch,et al.  Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. , 2006, European journal of endocrinology.

[30]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[31]  J. Folkman,et al.  Tumor angiogenesis: a possible control point in tumor growth. , 1975, Annals of internal medicine.

[32]  B. Zetter.  The scientific contributions of M. Judah Folkman to cancer research , 2008, Nature Reviews Cancer.

[33]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[34]  H. Modjtahedi,et al.  Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. , 2008, International journal of oncology.

[35]  G. Altavilla,et al.  Paclitaxel Is an Effective Antiproliferative Agent on the Human NCI-H295 Adrenocortical Carcinoma Cell Line , 1998, Chemotherapy.

[36]  I. Bourdeau,et al.  Frequent mutations of β‐catenin gene in sporadic secreting adrenocortical adenomas * , 2007, Clinical endocrinology.

[37]  J. Bertherat,et al.  Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. , 2008, The Journal of clinical endocrinology and metabolism.

[38]  S. Clark,et al.  Mutation and methylation analysis of TP53 in adrenal carcinogenesis. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  Paul G Gauger,et al.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. , 2003, The American journal of pathology.

[40]  P. Adam,et al.  Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. , 2008, The Journal of clinical endocrinology and metabolism.

[41]  A. Chase,et al.  Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.

[42]  S. Thomson,et al.  Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. , 2008, Cancer research.

[43]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[44]  D. Welch,et al.  Metastasis suppressor genes at the interface between the environment and tumor cell growth. , 2011, International review of cell and molecular biology.

[45]  Yan Tang,et al.  CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice , 2006, Clinical Cancer Research.

[46]  K. Shigematsu,et al.  Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. , 1990, Human pathology.

[47]  R. Kuick,et al.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[48]  Jeffrey M Trent,et al.  Adrenocortical carcinoma survival rates correlated to genomic copy number variants , 2008, Molecular Cancer Therapeutics.

[49]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[50]  Dan Theodorescu,et al.  Learning therapeutic lessons from metastasis suppressor proteins , 2009, Nature Reviews Cancer.

[51]  J. Bertherat,et al.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. , 2005, Cancer research.

[52]  K. Watabe,et al.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. , 2008, Biochimica et biophysica acta.

[53]  Ken Kato,et al.  Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer , 2008, Oncology.

[54]  J. Christensen,et al.  HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. , 2010, Cancer research.

[55]  R. D'Agostino.  Changing end points in breast-cancer drug approval--the Avastin story. , 2011, The New England journal of medicine.

[56]  C. J. Barnes,et al.  Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer , 2007, Clinical Cancer Research.

[57]  P. Casali,et al.  Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. , 2005, Endocrine-related cancer.